{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:39:18Z","timestamp":1788871158435,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,8,15]],"date-time":"2013-08-15T00:00:00Z","timestamp":1376524800000},"content-version":"vor","delay-in-days":348,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005189","name":"Leukemia and Lymphoma Society","doi-asserted-by":"publisher","award":["K08-DK067359"],"award-info":[{"award-number":["K08-DK067359"]}],"id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-HL67277-09"],"award-info":[{"award-number":["R01-HL67277-09"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007698","name":"University of Florida","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007698","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajp.amjpathol.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Pathology"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.ajpath.2012.05.033","type":"journal-article","created":{"date-parts":[[2012,7,13]],"date-time":"2012-07-13T09:08:05Z","timestamp":1342170485000},"page":"858-865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The Small Molecule Inhibitor G6 Significantly Reduces Bone Marrow Fibrosis and the Mutant Burden in a Mouse Model of Jak2-Mediated Myelofibrosis"],"prefix":"10.1016","volume":"181","author":[{"given":"Annet","family":"Kirabo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung O.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather L.","family":"Wamsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghanath","family":"Gali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebekah","family":"Baskin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary K.","family":"Reinhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhizhuang J.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirpal S.","family":"Bisht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gy\u00f6rgy M.","family":"Keser\u0171","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Cogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Sayeski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajpath.2012.05.033_bib1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/ajh.21129","article-title":"Prevalence of polycythemia vera and essential thrombocythemia","volume":"83","author":"Ma","year":"2008","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajpath.2012.05.033_bib2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I","article-title":"Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976\u20131995","volume":"61","author":"Mesa","year":"1999","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ajpath.2012.05.033_bib3","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ajpath.2012.05.033_bib4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2012.05.033_bib5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.ajpath.2012.05.033_bib6","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ajpath.2012.05.033_bib7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2012.05.033_bib8","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2012.05.033_bib9","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib; the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ajpath.2012.05.033_bib10","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ajpath.2012.05.033_bib11","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMc1109555","article-title":"Long-term outcome of treatment with ruxolitinib in myelofibrosis","volume":"365","author":"Tefferi","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ajpath.2012.05.033_bib12","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.1016\/j.bmcl.2009.04.138","article-title":"Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening","volume":"19","author":"Kiss","year":"2009","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.ajpath.2012.05.033_bib13","doi-asserted-by":"crossref","first-page":"31399","DOI":"10.1074\/jbc.M110.168211","article-title":"Structure-function correlation of G6, a novel small molecule inhibitor of Jak2: indispensability of the stilbenoid core","volume":"285","author":"Majumder","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2012.05.033_bib14","doi-asserted-by":"crossref","first-page":"7774","DOI":"10.1021\/bi200847n","article-title":"Cell death induced by the Jak2 inhibitor, G6, correlates with cleavage of vimentin filaments","volume":"50","author":"Majumder","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.ajpath.2012.05.033_bib15","doi-asserted-by":"crossref","first-page":"4280","DOI":"10.1074\/jbc.M110.200774","article-title":"The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo","volume":"286","author":"Kirabo","year":"2011","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ajpath.2012.05.033_bib16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1593\/neo.111112","article-title":"The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow","volume":"13","author":"Kirabo","year":"2011","journal-title":"Neoplasia"},{"key":"10.1016\/j.ajpath.2012.05.033_bib17","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1182\/blood-2007-05-091579","article-title":"Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice","volume":"111","author":"Xing","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.05.033_bib18","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1080\/01926230600939971","article-title":"Enhanced histopathology of the bone marrow","volume":"34","author":"Elmore","year":"2006","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.ajpath.2012.05.033_bib19","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.ajpath.2012.05.033_bib20","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"11","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.05.033_bib21","doi-asserted-by":"crossref","first-page":"5232","DOI":"10.1182\/blood-2009-05-223727","article-title":"CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms","volume":"115","author":"Tyner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.05.033_bib22","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ccr.2008.02.009","article-title":"Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera","volume":"13","author":"Wernig","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ajpath.2012.05.033_bib23","first-page":"557","article-title":"Preclinical and clinical activity of ATP mimetic JAK2 inhibitors","volume":"8","author":"Wadleigh","year":"2010","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ajpath.2012.05.033_bib24","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.blre.2011.06.002","article-title":"JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective","volume":"25","author":"Tefferi","year":"2011","journal-title":"Blood Reviews"},{"key":"10.1016\/j.ajpath.2012.05.033_bib25","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/blood-2009-10-246363","article-title":"Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera\/essential thrombocythemia myelofibrosis","volume":"115","author":"Santos","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.05.033_bib26","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1182\/blood-2009-04-218842","article-title":"Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis","volume":"115","author":"Koppikar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ajpath.2012.05.033_bib27","doi-asserted-by":"crossref","first-page":"4551","DOI":"10.2174\/092986710794182953","article-title":"The recent medicinal chemistry development of Jak2 tyrosine kinase small molecule inhibitors","volume":"17","author":"Baskin","year":"2010","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.ajpath.2012.05.033_bib28","first-page":"37","article-title":"New anticancer agents: in vitro and in vivo evaluation of the antitumor and antimetastatic actions of various compounds isolated from medicinal plants","volume":"19","author":"Kimura","year":"2005","journal-title":"In Vivo"},{"key":"10.1016\/j.ajpath.2012.05.033_bib29","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1021\/jf030073c","article-title":"Grape polyphenol resveratrol and the related molecule 4-hydroxystilbene induce growth inhibition, apoptosis","volume":"51","author":"Larrosa","year":"2003","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.ajpath.2012.05.033_bib30","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/mnfr.200400094","article-title":"Resveratrol and breast cancer chemoprevention: molecular mechanisms","volume":"49","author":"Le Corre","year":"2005","journal-title":"Mol Nutr Food Res"},{"key":"10.1016\/j.ajpath.2012.05.033_bib31","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0009-8981(95)06045-1","article-title":"The red wine phenolics trans-resveratrol and quercetin block human platelet aggregation and eicosanoid synthesis: implications for protection against coronary heart disease","volume":"235","author":"Pace-Asciak","year":"1995","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.ajpath.2012.05.033_bib32","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0006-291X(89)91060-7","article-title":"Piceatannol (3,4,3\u2032,5\u2032-tetrahydroxy-trans-stilbene) is a naturally occurring protein-tyrosine kinase inhibitor","volume":"165","author":"Geahlen","year":"1989","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ajpath.2012.05.033_bib33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/jac\/dkg306","article-title":"Identification of latent membrane protein 2A (LMP2A) specific targets for treatment and eradication of Epstein-Barr virus (EBV)-associated diseases","volume":"52","author":"Swanson-Mungerson","year":"2003","journal-title":"J Antimicrob Chemother"}],"container-title":["The American Journal of Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944012004397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002944012004397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T14:38:45Z","timestamp":1757601525000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002944012004397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":33,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0002944012004397"],"URL":"https:\/\/doi.org\/10.1016\/j.ajpath.2012.05.033","relation":{},"ISSN":["0002-9440"],"issn-type":[{"value":"0002-9440","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Small Molecule Inhibitor G6 Significantly Reduces Bone Marrow Fibrosis and the Mutant Burden in a Mouse Model of Jak2-Mediated Myelofibrosis","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajpath.2012.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Society for Investigative Pathology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}